Glioma trial of intranasal therapy NEO100 fills all patient slots
Neonc Technologies has completed enrollment for its Phase 2a clinical trial of NEO100, an intranasal treatment for high-grade glioma, the company announced. This follows…
Glioma
Tinostamustine named orphan drug for treating malignant gliomas
The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to tinostamustine, a treatment candidate from Purdue Pharma that aims to extend…
Oral safusidenib begins trial as maintenance for high-grade glioma
Enrollment has begun in the second part of a clinical trial testing safusidenib, an experimental oral treatment, as a maintenance therapy for high-grade IDH1-mutant astrocytoma,…
Therapy wins rare pediatric disease designation for hard-to-treat glioma
The U.S. Food and Drug Administration (FDA) has granted rare pediatric disease designation to iopofosine I 131 — now being tested in young people in…
Advocates urge action after NICE rejects Voranigo for England’s NHS
In a setback for brain tumor patients, England’s National Health Service (NHS) has been advised not to routinely cover the new cancer therapy Voranigo…
New treatment leads to longer survival for glioblastoma patients
In a small clinical trial involving individuals with recurrent glioblastoma — a highly aggressive form of glioma — patients who received a single injection…
FDA grants orphan drug designation to glioblastoma treatment
The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to an experimental therapy called cintredekin besudotox (IL13-PE38QQR), which Precision Neuromed is…
Iopofosine I 131 may improve survival in pediatric brain cancer
The experimental therapy iopofosine I 131Â may improve survival outcomes in children and young adults with hard-to-treat glioma, according to new clinical trial data announced…
Voranigo becomes 1st therapy in EU to target IDH-mutated glioma
The European Commission has approved Voranigo (vorasidenib) for certain types of glioma, marking the arrival of a new targeted pill poised to change…
Clinical trial testing BPM31510 for glioblastoma now fully enrolled
Enrollment is now complete in a Phase 2b clinical trial testing Bpgbio’s BPM31510, a treatment candidate for glioblastoma multiforme (GBM), a rapidly progressing type…
